1Melamed ML, Muntner P, Micho S, et al. Serum 25-hydroxyvitamin D lev- els and the prevalence of peripheral arterial discrse: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol,2008,28 : 1179- 1185.
2Lu L, Yu ZJ,Pan A, et al. Plasma 25-hydroxyvitamin I) concentration and metabolic syndrome among middle-aged and elderly Chinese individuals. Diabetes Care ,2009,32 : 1278-1283.
3Autier P,Gandini S. Vitamin Dsupplementation and total mortality:a me- ta-analysis of randomized controlled trials. Arch Intern Med,2007,167: 1730-1737.
4Carthy EP, Yamashita W, Hsu A, et al. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension, 1989,13:954-959.
5Mancuso P, Rahman A, Hershey SD, et al. 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone( cp/+ ) rats independent of changes in serum leptin. J Cardiovasc Pharmacol,2008 ,51:559-564.
6Wu-Wong JR, Nakane M, Ma J, et al. Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclemsis ,2006,186:20-28.
7Kim DH, Sabour S, Sagar UN, et al. Prevalence of hypovitaminosis D in cardiovascular diseases( from the National Health and Nutrition Examina- tion Survey 2001 to 2004). Am J Cardiol,2008,102 : 1540-1544.
8Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens,2007 ,20 :713-719.
9Reis JP, Mtlhlen D, Miller ER, et al. Vitamin D status and cardiometabol- ic risk factors in the United States adolescent population P. Ediatrics, 2009,124 : e371-379.
10Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the reninangiotensin system. J Clin Invest,2002, 110:229-238.
